<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03075644</url>
  </required_header>
  <id_info>
    <org_study_id>NN8640-4244</org_study_id>
    <secondary_id>U1111-1181-1618</secondary_id>
    <secondary_id>JapicCTI-173534</secondary_id>
    <nct_id>NCT03075644</nct_id>
  </id_info>
  <brief_title>A Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone Deficiency</brief_title>
  <official_title>A Multicentre, Randomised, Open-labelled, Parallel-group, Activecontrolled Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Asia. The aim of this trial is to evaluate the safety of once
      weekly dosing of somapacitan (NNC0195-0092) and daily Norditropin® FlexPro® for 52 weeks in
      previously human growth hormone treated Japanese adults with growth hormone deficiency.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 3, 2017</start_date>
  <completion_date type="Anticipated">October 5, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 28, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events, including injection site reactions</measure>
    <time_frame>Week 0 - week 53</time_frame>
    <description>Count and % of events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in cross-sectional total adipose tissue compartments (TAT)</measure>
    <time_frame>Week 0, Week 52</time_frame>
    <description>The change is determined by quantitative computed tomography (CT) scans</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in subcutaneous adipose tissue compartments (SAT)</measure>
    <time_frame>Week 0, Week 52</time_frame>
    <description>The change is determined by quantitative computed tomography (CT) scans</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in intra-abdominal or visceral adipose tissue compartments (VAT)</measure>
    <time_frame>Week 0, Week 52</time_frame>
    <description>The change is determined by quantitative computed tomography (CT) scans</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Treatment Satisfaction Questionnaire for Medication (TSQM-9) scores for effectiveness</measure>
    <time_frame>Week 0, Week 52</time_frame>
    <description>Treatment satisfaction questionnaire for medication-contains 9 items</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in TSQM-9 scores for convenience</measure>
    <time_frame>Week 0, Week 52</time_frame>
    <description>Treatment satisfaction questionnaire for medication-contains 9 items</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in TSQM-9 scores for global satisfaction</measure>
    <time_frame>Week 0, Week 52</time_frame>
    <description>Treatment satisfaction questionnaire for medication-contains 9 items</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Growth Hormone Disorder</condition>
  <condition>Adult Growth Hormone Deficiency</condition>
  <arm_group>
    <arm_group_label>Somapacitan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Norditropin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>somapacitan</intervention_name>
    <description>Once weekly subcutaneous injections (s.c., under the skin)</description>
    <arm_group_label>Somapacitan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norditropin</intervention_name>
    <description>Daily subcutaneous injections (s.c., under the skin)</description>
    <arm_group_label>Norditropin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female of at least 18 years of age and not more than 79 years of age at the
             time of signing informed consent

          -  GHD diagnosed for at least 6 months (defined as 180 days) prior to screening

          -  Treatment with hGH for at least 6 consecutive months (defined as 180 days) at
             screening

          -  If applicable, hormone replacement therapies for any other hormone deficiencies,
             adequate and stable for at least 90 days prior to randomisation as judged by the
             investigator

        Exclusion Criteria:

          -  Active malignant disease or history of malignancy. Exceptions to this exclusion
             criterion:1/ Resected in situ carcinoma of the cervix and squamous cell or basal cell
             carcinoma of the skin with complete local excision 2/ Subjects with GHD attributed to
             treatment of intracranial malignant tumours or leukaemia, provided that a
             recurrence-free survival period of at least 5 years is documented in the subject's
             medical records

          -  For subjects with surgical removal or debulking of pituitary adenoma or other benign
             intracranial tumour within the last 5 years:Evidence of growth of pituitary adenoma or
             other benign intracranial tumour within the last 12 months (defined as below or equal
             to 365 days) before randomisation. Absence of growth must be documented by two
             post-surgery magnetic resonance imaging (MRI) scans or CT scans. The most recent MRI
             or CT scan must be performed below or equal to 9 months (defined as below or equal to
             270 days) prior to randomisation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bunkyo-ku, Tokyo</city>
        <zip>113-8603</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Chiba-shi, Chiba</city>
        <zip>260-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>818 8502</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kagoshima</city>
        <zip>890-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kobe, Hyogo</city>
        <zip>650-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kyoto-shi Kyoto</city>
        <zip>612-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Okayama, Okayama</city>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Osaka</city>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Sagamihara-shi, Kanagawa</city>
        <zip>252-0375</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>134-0088</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Yamagata-shi, Yamagata</city>
        <zip>990-9585</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Yokohama, Kanagawa</city>
        <zip>222-0036</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2017</study_first_submitted>
  <study_first_submitted_qc>March 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2017</study_first_posted>
  <last_update_submitted>October 5, 2017</last_update_submitted>
  <last_update_submitted_qc>October 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endocrine System Diseases</mesh_term>
    <mesh_term>Dwarfism, Pituitary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the Novo Nordisk disclosure commitment on novonordisk-trials.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

